TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8189732
Drug: Alcohol (actual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (actual and expected doses)
Study: 2438221
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (VBP regimen)
Study: 28034894
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml water ingestion
Study: 28034894
Drug: Angiopoietin-1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiopoietin-1 treatment
Study: 28034894
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml normal saline ingestion
Study: 28034894
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml water ingestion
Study: 23819337
Drug: Genetically engineered
Normalized name: Genetically Engineered Herpes Simplex Virus
DrugBank: G207 (DB05827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically engineered biological agents (GEBAs), primarily rituximab (n = 66) and infliximab (n = 31)
Study: 23819337
Drug: Genetically engineered
Normalized name: Genetically Engineered Herpes Simplex Virus
DrugBank: G207 (DB05827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically engineered biological agents (GEBAs)
Study: 21694461
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (after 8 weeks of low-dose vitamin D 1000 IU/day)
Study: 21694461
Drug: Nasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal insulin (60 IU qid for 48 hours after high-dose vitamin D)
Study: 21694461
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after high-dose vitamin D)
Study: 21694461
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after nasal insulin)
Study: 16153694
Drug: Intraperitoneal alpha-interferon
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal alpha-interferon (50 x 10(6) IU weekly for 6 doses)
Study: 9377133
Drug: Cisapride (1.4‐2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (1.4‐2.3 mg/kg/day)
Study: 8266226
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms dose of hepatitis B vaccine
Study: 8266226
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms dose of hepatitis B vaccine
Study: 31114673
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) and home exercise
Study: 31114673
Drug: Combination groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination groups (SMT + home exercise, supervised rehabilitative exercise + home exercise)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (rehabilitation)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (enabling)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (review)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (assessment)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (supportive)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (activity to support therapy)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (overall therapy received)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (delivery personnel)
Study: 29990345
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (session type)
Study: 27485453
Drug: CY 2
Normalized name: Clearskin Emergency 2 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY 2 g/m(2) + G-CSF (arm A)
Study: 24862733
Drug: HVAD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVAD and ICD therapy
Study: 8100914
Drug: Low-dose allopurinol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose allopurinol (25 mg on alternative days) plus triple immunosuppression (cyclosporin, prednisolone, azathioprine)
Study: 8100914
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy alone (cyclosporin, prednisolone, azathioprine)
Study: 25603438
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution placebo
Study: 23335738
Drug: Anidulafungin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (200 mg loading dose on day 1, followed by 100 mg daily maintenance dose)
Study: 23335738
Drug: Anidulafungin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (150 mg daily maintenance dose for 240-kg patient)
Study: 16835748
Drug: Octreotide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (30 mg) alone monthly
Study: 16835748
Drug: Octreotide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (30 mg) in combination with rofecoxib (up to 50 mg bid daily)
Study: 9922303
Drug: OAC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC group (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin)
Study: 9922303
Drug: OMC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC group (20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Study: 9922303
Drug: AC group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC group (1000 mg amoxicillin, 500 mg clarithromycin)
Study: 9922303
Drug: MC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC group (400 mg metronidazole, 250 mg clarithromycin)
Study: 7917508
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) administered immediately after astemizole ingestion
Study: 7917508
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of activated charcoal (12 g) administered twice daily for 8 days
Study: 31934821
Drug: Nattospes as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattospes as an adjuvant to standard of care (SOC) treatment
Study: 31934821
Drug: Nattospes as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattospes as an adjuvant to SOC treatment
Study: 25156179
Drug: SPS-Mg
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPS-Mg
Study: 21472620
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration therapy (FitVibe medical™)
Study: 21472620
Drug: Standardised rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised rehabilitation therapy with pelvic floor re-education (control group)
Study: 17881186
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg plus long-acting propranolol 80mg
Study: 17881186
Drug: Aspirin 100mg
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg plus placebo
Study: 7706598
Drug: Restricted intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intake of thiamin, riboflavin, and vitamin B6 (daily diet providing no more than 55% of the Dutch RDA for these vitamins)
Study: 7706598
Drug: Regular intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intake of vitamins (supplemented at twice the RDA level)
Study: 24090588
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg per day in month 1, 20 mg per day in month 2, and 20-40 mg per day in months 3-12)
Study: 19035858
Drug: Degarelix 240/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix 240/160 mg
Study: 8799526
Drug: Artemisinin monotherapy
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin monotherapy (500 mg single dose followed by another 500 mg on day 1 and then 250 mg twice daily for 4 days)
Study: 8799526
Drug: Artemisinin in
Normalized name: Product containing artemisinin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin in combination with mefloquine (500 mg single dose followed by 750 mg on day 1 and then 250 mg three times daily for one more day; Mefloquine 250 mg three times daily for the first day)
Study: 8799526
Drug: Artemisinin monotherapy
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin monotherapy
Study: 8799526
Drug: Artemisinin in
Normalized name: Product containing artemisinin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin in combination with mefloquine
Study: 1633906
Drug: Glucocorticoids (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (group A) - intravenous hydrocortisone, 100 mg immediately after ultrasound-directed oocyte recovery, followed by prednisolone, 10 mg three times per day for 5 days, then 10 mg two times a day for 3 days, and 10 mg/d for 2 days.
Study: 1633906
Drug: No glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucocorticoid treatment (group B).
Study: 1633906
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received luteal support with intramuscular injections of gestone 100 mg/d.
Study: 1633906
Drug: No glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucocorticoid treatment (group B)
Study: 6640552
Drug: Human lymphoblastoid
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human lymphoblastoid interferon at a dose of 3.0 X 10(6) units/m2 three times/week for 6 weeks, followed by maintenance treatment with interferon (3.0 X 10(6) units/m2 once/week) for those who did not progress.
Study: 6640552
Drug: Placebo maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maintenance (no further treatment) for patients who did not progress after initial treatment.
Study: 21443602
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg once daily for 12 or 24 weeks
Study: 21443602
Drug: Alitretinoin 10
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 10 mg once daily for 12 or 24 weeks
Study: 19840748
Drug: 1g daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1g daily vitamin C treatment (Group II)
Study: 19840748
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin C treatment (Group I)
Study: 16490844
Drug: Anti-CTLA-4 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CTLA-4 monoclonal antibody (up to 9 mg/kg every 3 weeks)
Study: 10927048
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg)
Study: 10927048
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate (3.75 mg)
Study: 4646510
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (emphasizing good prognosis, early mobilization, physiotherapy)
Study: 4646510
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (physiotherapy)
Study: 28974406
Drug: CCH 0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH 0.58 mg plus vacuum therapy alone
Study: 28974406
Drug: CCH 0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH 0.58 mg plus vacuum therapy with penile modeling
Study: 19833276
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (0.1 mL/kg of preservative‐free 1% lidocaine pretreatment, slow rocuronium injection)
Study: 19833276
Drug: Group R
Normalized name: Typhus group rickettsia Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group R (0.1 mL/kg of 0.9% NaCl pretreatment, rapid rocuronium injection)
Study: 19833276
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (0.1 mL/kg of 0.9% NaCl pretreatment, slow rocuronium injection)
Study: 19833276
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L vs Group R
Study: 9252801
Drug: Tolcapone with
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone with standard-release levodopa/benserazide formulations (50/12.5 mg, 100/25 mg, 200/50 mg)
Study: 9252801
Drug: Tolcapone with
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone with controlled-release levodopa/benserazide formulation (100/25 mg)
Study: 8060907
Drug: Empathy-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empathy-treatment
Study: 8060907
Drug: Facts-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facts-treatment
Study: 20029208
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo with pantoprazole rescue (n = 141)
Study: 20029208
Drug: Daily pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pantoprazole with placebo rescue (n = 62)
Study: 3920861
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Sorbinil
Study: 20589494
Drug: Tramadol 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 800 mg/day
Study: 20589494
Drug: Hydromorphone (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (1.5, 3.0, and 6.0 mg)
Study: 15699233
Drug: Men not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men not choline depleted (550 mg choline/d)
Study: 10690245
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) + Ivermectin (200 micrograms/kg)
Study: 10690245
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) + DEC (6 mg/kg)
Study: 8699911
Drug: Topical pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pilocarpine (candy-like pastille) administered in increasing dosages for 5 weeks
Study: 8699911
Drug: Topical pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pilocarpine (candy-like pastille)
Study: 8699911
Drug: Topical pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pilocarpine administration
Study: 1873372
Drug: 100 mcg
Normalized name: Levo-T 100 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg selenium daily for 5 weeks
Study: 31815649
Drug: Upadacitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (both doses)
Study: 29182407
Drug: Metformin (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (conventional anti-diabetic doses)
Study: 29182407
Drug: Control (non-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-treatment mixed)
Study: 24799181
Drug: HAL photodynamic
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HAL photodynamic therapy (PDT) with vaginal suppository, 5 hours before illumination with 50 J/cm² red coherent light (633 nm)
Study: 24799181
Drug: HAL photodynamic
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HAL photodynamic therapy (PDT)
Study: 15876944
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/d for 3 days weekly, for 3 weeks) with symptom-specific agents
Study: 15876944
Drug: Symptom-specific agents
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-specific agents alone
Study: 9498512
Drug: 600 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU/kg intravenous EPO three times weekly
Study: 1978371
Drug: Ipsapirone 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 15 mg
Study: 1978371
Drug: Ipsapirone 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 30 mg
Study: 29178943
Drug: High-volume hemofiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume hemofiltration (HVHF) at a dose of 70 ml/kg/hour for 48 hours
Study: 19134020
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Bifidobacterium longum (BL999) 1 x 10(7) CFU/g and Lactobacillus rhamnosus (LPR) 2 x 10(7) CFU/g)
Study: 11642024
Drug: Vancomycin (23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (23 F per gram) in continuous infusion through a central venous catheter
Study: 11642024
Drug: Teicoplanin (311‐357
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (311‐357 F a 400 mg vial) intramuscularly
Study: 3058475
Drug: Propofol 1‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1‐1.5 mg kg‐1 body weight
Study: 3058475
Drug: Methohexitone 0.75‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone 0.75‐1 mg kg‐1 body weight
Study: 24253484
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 60 mg daily
Study: 23860961
Drug: Alprostadil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (0.4 μg/kg/day) in 100 ml sterile saline
Study: 16623075
Drug: Irbesartan/HCTZ treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ treatment
Study: 11336155
Drug: Jejunal meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal meal feeding (liquid meal at 2 kcal/2 ml/min)
Study: 8204290
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg b.d. for 8 days (25 patients)
Study: 8204290
Drug: Amoxycillin/clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate 500 mg t.d.s for 8 days (22 patients)
Study: 21427078
Drug: C24T variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: C24T variant allele in MRP2 under macrolides treatment (Tacrolimus and Sirolimus)
Study: 21427078
Drug: C24T variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: C24T variant allele in MRP2 under cyclosporine treatment
Study: 22713999
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus ibuprofen (AcIBU)
Study: 18308218
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus codeine plus caffeine (Tylenol No. 3)
Study: 10875715
Drug: Morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.15 mg x kg(‐1) (R/M15 group)
Study: 10875715
Drug: Morphine 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.20 mg x kg(‐1) (R/M20 group)
Study: 23062389
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol 320 μg/day
Study: 23062389
Drug: Placebo/prednisone (prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/prednisone (prednisone 10 mg/day for the last 7 days)
Study: 16823241
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV administration of NIC
Study: 16823241
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV and oral administration of NIC
Study: 16823241
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with NIC (Control group)
Study: 15678619
Drug: Avasimibe 50
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe 50 mg
Study: 15678619
Drug: Avasimibe 250
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe 250 mg
Study: 15678619
Drug: Avasimibe 750
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe 750 mg
Study: 8978584
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg plus dexamethasone 20 mg (8 mg group)
Study: 8978584
Drug: Ondansetron 24
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 24 mg plus dexamethasone 20 mg (24 mg group)
Study: 23199009
Drug: 0.5‐1.0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5‐1.0 μg calcitriol and 1,200 IU (30 μg) cholecalciferol
Study: 20572581
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with daily low-dose carboplatin (arm II)
Study: 20572581
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with daily low-dose carboplatin (arm II) in stage IV disease
Study: 16532872
Drug: Shin Saver
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shin Saver orthosis treatment group
Study: 3536293
Drug: Trientine 300
Normalized name: trientine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trientine 300 mg daily